Learn / Withdrawal and Discontinuation
Withdrawal and discontinuation
Stopping is also a medication event
Discontinuation is documented. Severity varies. Relapse and withdrawal can resemble one another. Withdrawal is not synonymous with addiction. This site will not write you a taper.
A medicine’s last chapter is still part of the treatment. That fact has been easier to ignore than to record. People are often asked to reconstruct a reduction from memory, in a ten-minute appointment, while still living inside it.
1 · Statement
Stopping or reducing many antidepressants can be followed by discontinuation symptoms in a substantial minority of people. Estimates of how often this happens vary widely by study method. Withdrawal is not the same as addiction, and it is not automatically the same as relapse.
2 · Classification
Established. Recognised in guidelines. Incidence estimates differ (survey syntheses vs placebo-adjusted meta-analysis).
3 · Papers
4 · Claim limitation
Symptoms overlap with relapse, anxiety and sleep disruption. Individual attribution remains uncertain.
Where evidence disagrees
Davies and Read (2019) reported withdrawal incidence estimates from 27% to 86% across mixed study designs, with a weighted average of 56%. Henssler et al. (2024), after accounting for symptoms also reported after stopping placebo, estimated about 15%, with severe symptoms in about one in 35. Both papers stay in this library. The disagreement is the finding. Incidence is not causation in an individual, and neither estimate is a tapering schedule.
Last reviewed
1 September 2026
What people report after reductions
Recognised discontinuation phenomena can include dizziness, nausea, sleep change, anxiety, agitation, irritability, sensory disturbances (including electric-shock-like sensations for some people), concentration change, and mood change. Lists are not checklists. Presence of a symptom on a list does not prove withdrawal. Absence of a listed symptom does not prove it is not happening.
Incidence is contested, existence is not
Davies and Read (2019) synthesised higher incidence estimates from mixed study designs. Henssler and colleagues (2024) estimated a lower incidence after attempting to account for symptoms also reported after stopping placebo. Both papers are in the library. The disagreement is information. It is not a reason to tell an individual that what they are experiencing is imaginary, and it is not a reason to tell them it is definitely withdrawal.
1 · Statement
For many antidepressants, staged dose reduction is commonly recommended rather than abrupt cessation. Paradoxical.life does not provide an individual tapering schedule.
2 · Classification
Established. Present in major depression guidelines and in discontinuation literature.
3 · Papers
4 · Claim limitation
How slowly, and with which formulation, is an individual clinical decision.
Last reviewed
1 September 2026
If you miss a dose, record what happened afterwards as an experience following a missed dose. Do not let the form pre-label it as withdrawal. Attribution is a clinical conversation.
Sources used on this page
- National Institute for Health and Care Excellence (NICE) (2022). Depression in adults: treatment and management (NG222).
- Horowitz MA, Taylor D (2019). Tapering of SSRI treatment to mitigate withdrawal symptoms.
- Davies J, Read J (2019). A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?.
- Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C (2024). Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis.
- Australian ADHD Professionals Association (AADPA) (2022). Australian Evidence-Based Clinical Practice Guideline For Attention Deficit Hyperactivity Disorder (ADHD).
Paradoxical.life provides evidence and self-documentation tools, not medical advice. If you have concerns about your health, medication or mental state, speak with a qualified medical practitioner.